scholarly journals The direct medical cost of breast cancer in a Belgian hospital

2019 ◽  
Vol 30 ◽  
pp. v680
Author(s):  
H. Lemhouer ◽  
D M E C Verhoeven ◽  
V. Corluy ◽  
D. De Graeve
Keyword(s):  
Breast Cancer ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Belgian Hospital

scholarly journals PCN75 Direct Medical Cost of Breast Cancer in Saudi Arabia

2020 ◽  
Vol 23 ◽  
pp. S435
Author(s):  
A. Alghamdi ◽  
S. Alqahtani
Keyword(s):  
Breast Cancer ◽  
Saudi Arabia ◽  
Direct Medical Cost ◽  
Medical Cost

scholarly journals Analisis Cost-Effectiveness Seftazidim Generik pada Pasien Kanker Payudara di Rumah Sakit Kanker “Dharmais” Jakarta, 2012

2016 ◽  
Vol 10 (3) ◽  
pp. 113
Author(s):  
NADIA FARHANAH SYAFHAN ◽  
AGUSDINI BANUN SAPTANINGSIH ◽  
MUTIARA JEANY RAHAYU PERTIWI
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Direct Medical Cost ◽  
Cancer Patients ◽  
Medical Cost ◽  
Late Stage ◽  
Early Stage ◽  
Cost Effective ◽  
Breast Cancer Patients ◽  
Total Direct Medical Cost

ABSTRACTAdministration of ceftazidime shortened duration of neutropenia and hospitalization days in breast cancer patients who had infection after myelosupressive chemotherapy. Cost-effectiveness analysis (CEA) as one of pharmacoeconomic methods was important to determine treatment attaining effect for lower cost. The aim of this study was to comparethe total direct medical cost and effectiveness, which was measured from length-of-stay (LOS), of generic ceftazidime A and B usage, and to decide which ceftazidime that was more cost-effective in early-stage and late-stage breast cancer patients at National Cancer Center Dharmais Hospital Jakarta year 2012. The study design was non-experimental withcomparative study retrospectively on secondary data from medical records and administrative data in 2012. Samples were taken by using total sampling method. The number of samples were 9 patients, which included 7 patients with generic ceftazidime A and 2 patients with generic ceftazidime B. The total direct medical cost of generic ceftazidime A in early-stage and late-stage breast cancer patients, respectively Rp 15.930.407,45 and Rp 15.962.519,25, were higher than generic B, respectively Rp 6.716.225,21 and Rp 7.147.956,92. Median LOS of generic A ceftazidime in early-stage and late-stage breast cancer patients, respectively 7 days and 10 days, were longer than generic B, respectively 3 days and 4 days. According to CEA result, generic ceftazidime B was more cost-effective than generic A.ABSTRAKPemberian seftazidim dapat mempersingkat durasi neutropenia dan lama hari rawat inap pada pasien kanker payudara yang mengalami infeksi setelah kemoterapi mielosupresif. Analisis cost-effectiveness merupakan salah satu metode farmakoekonomi yang penting untuk menentukan obat efektif dengan biaya yang lebih rendah. Penelitian dilakukan untuk membandingkan total biaya medis langsung dan efektivitas yang dilihat dari lama hari rawat penggunaan seftazidim generik A dan B, serta menentukan seftazidim yang lebih cost-effective pada pasien kanker payudara stadium awal dan lanjut di Rumah Sakit Kanker “Dharmais” Jakarta, 2012. Desain penelitian yang digunakan adalah studi komparatif secara retrospektif terhadap data rekam medis dan administrasi tahun 2012. Pengambilan sampel dilakukan secara total sampling. Jumlah pasien yang dilibatkan dalam analisis 9 pasien, yaitu 7 pasien menggunakan seftazidim generik A dan 2 pasien menggunakan seftazidim generik B. Median total biaya medis langsung kelompok generik A pada pasien kanker stadium awal maupun lanjut berturut-turut sebesar Rp 15.930.407,45 dan Rp 15.962.519,25 lebih tinggi dibanding generik B, berturut-turut sebesar Rp 6.716.225,21 dan Rp 7.147.956,92. Median lama hari rawat kelompok generik A pada pasien kanker stadium awal maupun lanjut berturut-turut 7 hari dan 10 hari, lebih panjang dibanding generik B, berturut-turut 3 hari dan 4 hari. Berdasarkan hasil penelitian disimpulkan bahwa seftazidim generik B lebih cost-effective dibanding generik A.

scholarly journals PCN52 DIRECT MEDICAL COST OF BREAST CANCER BY STAGE OF CLINICAL DISEASE. A MEXICAN COHORT

2008 ◽  
Vol 11 (3) ◽  
pp. A70
Author(s):  
L Cortés-Sanabria ◽  
H Soto-Molina ◽  
K De la Cruz-Aguirre ◽  
E Salas-Gonzalez ◽  
G Aguayo-Alcaraz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Clinical Disease

Developing National Estimates of the Out-of-Pocket Costs of Cancer: The Importance of Including Patients with Lymphoma.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3138-3138
Author(s):  
Kathryn R. McCaffrey ◽  
Kenneth R. Carson ◽  
Lucie Kutikova ◽  
Matt Fisher ◽  
Simon Pickard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Medical Care ◽  
Direct Medical Cost ◽  
Cancer Patients ◽  
Medical Cost ◽  
Medical Costs ◽  
Breast Cancer Patients ◽  
Direct Medical Costs ◽  
12Th Grade ◽  
Out Of Pocket Costs

Abstract Background: While Congress has mandated that the NIH provide a national estimate of the cost of cancer, almost all cancer cost studies have focused exclusively on breast cancer. No study has reported comparison data for persons with Hodgkin’s disease (HD) or non-Hodgkin’s lymphoma (NHL). These illnesses have a high cure rate, and affected persons are likely to experience significant economic hardships. Many participate in the workforce during treatment and long after the treatment is complete. Herein, we report preliminary results from an ongoing study on the out-of-pocket direct medical and non-medical costs for a cohort of patients with lymphoma and provide contextual comparison with a cohort of breast cancer patients who received care at the same cancer center (Arozullah, Supportive Oncology, 2004). Methods: 178 breast cancer and lymphoma patients provided information on out-of-pocket costs for the preceding 3-month period; 12% had a diagnosis of HD or NHL. In total, 120 lymphoma patients will be interviewed for this study. Direct medical costs are costs related to medical care such as medications, procedures, and doctor visits. Direct non-medical costs are costs related to cancer, but not medical care, such as costs for meals, transportation, parking, and phone calls. Results: The majority of both lymphoma and breast cancer patients were < 65 years old, married, and employed. All patients had healthcare insurance coverage, with the majority insured with private plans. In comparison to women with breast cancer, persons with HD/NHL had similar mean monthly out-of-pocket cost expenditures, $635 versus $728. For lymphoma patients, factors associated with high direct medical costs included ≤ 12th grade education ($1,585/month) and HD ($1,133/month). Conclusion: Mean monthly out-of-pocket expenditures are similar for HD/NHL and breast cancer. Direct medical out-of-pocket expenditures for lymphoma vary. Direct medical expenditures are greatest for HD ($1,130), intermediate for aggressive NHL and breast cancer ($512–$597), and lowest for indolent NHL ($180). Comprehensive economic analyses of cancer should include a range of malignancies. Average Monthly Out-of-Pocket Costs for Lymphoma and Breast Cancer Patients. Direct Medical Cost Direct Medical Cost Direct Non-Medical Cost Direct Non-Medical Cost Lymphoma Breast Lymphoma Breast Household Income < $60,000 $381 $664 $40 $111 ≥ $60,000 $599 $553 $159 $161 Education ≤ 12th grade $1,585 $610 $72 $118 > 12th grade $437 $653 $141 $122 Diagnosis < 6 Months $577 $487 $114 $135 ≥ 6 Months $333 $660 $128 $130 Total Lymphoma $516 .. $119 .. HD $1,133 .. $155 .. AggressiveNHL $512 .. $167 .. Indolent NHL $180 .. $166 .. Total Breast Cancer .. $597 .. $131

scholarly journals PMS22 Direct Medical Cost of Osteoporosis in Saudi Arabia: A Single-Center Retrospective Cost Analysis

2020 ◽  
Vol 23 ◽  
pp. S596
Author(s):  
B. Balkhi ◽  
S. Alqusair ◽  
B. Alotaibi ◽  
A. Alghamdi ◽  
Y. AlRuthia ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Cost Analysis ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Single Center

scholarly journals EVALUATION OF PHARMACOECONOMIC DIRECT COST IN DIABETES PATIENTS

2017 ◽  
Vol 10 (4) ◽  
pp. 38
Author(s):  
Venkateswarlu Konuru ◽  
Kamala Sangam ◽  
Anifa Mohammed ◽  
Swathi Kanneganti
Keyword(s):  
Health Care ◽  
Diabetic Patient ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Average Cost ◽  
Health Care Cost ◽  
Vascular Complications ◽  
Illness Study ◽  
Total Average Cost ◽  
Total Average

Objective:  Diabetes Mellitus (DM) is a major cause of disability, morbidity and mortality Worldwide. The objective of this study is to evaluate the Pharmacoeconomic direct health care cost in type II Diabetes with complications and Diabetes alone: A cost of illness study. Methods:  A Prospective observational study was conducted for one year at the Care diabetes Center; Warangal. The enrolled patients were followed and the information collected contains: total direct costs, which include direct medical costs and direct nonmedical cost. The data observed was analyzed for the average cost incurred in treating the diabetic patient. Results:  The total average costs per diabetic patient without complications was Rs. 8695.7±1341,  this includes the average direct medical cost Rs. 6366.50± 561.12, the average lab cost Rs. 1368.84±64.8, the average direct non Medical Cost was Rs. 960.36±14.04 compared to  those with DM complications,the total average cost was Rs. 12960.73±549.96 for macro vascular complications, Rs. 11039.11±265.36 for micro vascular complications. To treat Diabetes with comorbidities which include both micro and macro complications the total average cost was  Rs. 16658.13±1393.44, the average direct medical cost was Rs. 14071.77±2884.68, the average lab cost Rs. 1628.04±51, the average direct non Medical Cost was Rs.958.32±13.08. The costs were found to increase progressively with the increase in the number of complications. Costs also differed significantly across the types of complications. Conclusion: Our study concludes that the cost of Diabetes with complications resulted about 2 times higher than compared to Diabetes alone.Key words:  Cost analysis; diabetes; economics; health care; direct medical cost; non medical cost

scholarly journals Direct medical cost of radiation therapy for cancer patients in Taiwan

Health ◽  
2013 ◽  
Vol 05 (06) ◽  
pp. 989-993
Author(s):  
Henry W. C. Leung ◽  
Agnes L. F. Chan
Keyword(s):  
Radiation Therapy ◽  
Direct Medical Cost ◽  
Cancer Patients ◽  
Medical Cost

scholarly journals Economic Burden of Tuberculosis Diabetes Co-Morbidity in Tuberculosis Patients Attending Two Chest Clinics in Lagos State

2021 ◽  
Vol 16 (2) ◽  
pp. 91-100
Author(s):  
F.A. Ayeni ◽  
O.O. Oyetunde ◽  
B.A. Aina ◽  
H.O. Yarah
Keyword(s):  
Direct Medical Cost ◽  
Medical Cost ◽  
Indirect Costs ◽  
Medical Costs ◽  
Female Patients ◽  
Direct Medical Costs ◽  
Tb Treatment ◽  
Co Morbidity ◽  
Lagos State ◽  
Significant Burden

Background: Diabetes mellitus (DM) increases the risk of developing tuberculosis (TB) three-fold. The cost of accessing care for TB-DM co-morbidity poses a significant burden on patients, as they bear both direct and indirect costs of treatment, mostly of out-of-pocket.Objective: To estimate the direct medical cost of illness in patients with TB-DM co-morbidity in two chest clinics in Lagos State.Materials and Methods: An observational study, carried out in two chest clinics in Lagos State to evaluate direct medical costs associated with TBDM co-morbidity during TB treatment. A semi structured questionnaire, pharmacy price list of drugs and an online transportation service lara.ng was employed to document and quantify prescribed medications, laboratory investigations, number of clinic attendance and attendant transportation costs.Results: Among the participants, 53.8% were females. The mean age was 50.7±9.7 years. The total direct medical and non-medical costs for TBDM management was NGN8,604,819 (USD24,585.20) for the duration of TB treatment. Average cost per patient (CPP) was NGN179,384.85 (USD512.53). This was equivalent to 49.8% of the current national minimum wage. Male patients incurred more mean direct medical cost than female patients (NGN26, 647.90 vs NGN24, 020.40), while female patients incurred more mean direct non-medical costs than the males (NGN22, 314.30 versus NGN13, 041.70). Patients aged 60 years and above incurred the highest mean direct costs compared to other age groups.Conclusion: Direct medical costs are substantial in TBDM co-morbidity and increase with age.

Sign in / Sign up

Export Citation Format

Share Document